Author

Raf Crabbé

Observed names: R CRABBE, R Crabbe, R Crabbé, R. CRABBÉ, R. Crabbe, R. Crabbé, Raf Crabbe, Rafael Crabbe, Rafael Crabbé

Observed institutions: Leiden University, Microsoft (United States), Janssen (Belgium), Medical University of Białystok, Henry Ford Health, University of Freiburg, Debiopharm (Switzerland), Weill Cornell Medicine, Chugai Pharmaceutical Co., Ltd. (Japan)

OpenAlex ID: A5110158105

The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients #

2009 · Robert Flisiak, Saya V. Feinman, et al. · Hepatology · 228

PDF

The cyclophilin inhibitor Debio-025 shows potent anti–hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus

2008 · Robert Flisiak, Andrzej Horban, et al. · Hepatology · 227

Randomised clinical trial: Bifidobacterium lactis NCC2818 probiotic vs placebo, and impact on gut transit time, symptoms, and gut microbiology in chronic constipation

2018 · Eirini Dimidi, Ausra Zdanaviciene, et al. · Alimentary Pharmacology & Therapeutics · 83

4 Once Daily Alisporivir (deb025) Plus Pegifnalfa2a/ribavirin Results in Superior Sustained Virologic Response (svr24) in Chronic Hepatitis C Genotype 1 Treatment Naive Patients

2011 · R. Flisiak, J.-M. Pawlotsky, et al. · Journal of Hepatology · 54

PDF

Cyclophilin inhibitors in hepatitis C viral infection

2007 · Robert Flisiak, Jean-Maurice Dumont, et al. · Expert Opinion on Investigational Drugs · 44

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C

2008 · Raf Crabbé, Grégoire Vuagniaux, et al. · Expert Opinion on Investigational Drugs · 37

143 Efficacy and Safety of Increasing Doses of the Cyclophilin Inhibitor Debio 025 in Combination With Pegylated Interferon Alpha-2a in Treatment Naive Chronic Hcv Patients

2008 · R. Flisiak, S.V. Feinman, et al. · Journal of Hepatology · 26

Analysis of the human KCNH2(HERG) gene: Identification and characterization of a novel mutation Y667X associated with long QT syndrome and a non-pathological 9 bp insertion Communicated by: Mark H. Paalman Online Citation: Human Mutation, Mutation in Brief #325 (2000) Online http://journals.wiley.com/1059-7794/pdf/mutation/325.pdf

2000 · Aim�e Paulussen, Ping Yang, et al. · Human Mutation · 23

PDF

95 Efficacy and Safety of the Cyclophilin Inhibitor Debio 025 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Previously Null-responder Genotype 1 Hcv Patients

2009 · D.R. Nelson, R.H. Ghalib, et al. · Journal of Hepatology · 22

Transdermal Permeation of Alniditan by Iontophoresis: In Vitro Optimization and Human Pharmacokinetic Data

1996 · Anne Jadoul, Jean Mesens, et al. · Pharmaceutical Research · 22

Recombinant human growth hormone for children born small for gestational age: Meta-analysis confirms the consistent dose-effect relationship on catch-up growth

2008 · R. Crabbé, M. von Holtey, et al. · Journal of Endocrinological Investigation · 16

Short-Term Daily Intake of Polydextrose Fiber Does Not Shorten Intestinal Transit Time in Constipated Adults: A Randomized Controlled Trial

2018 · Peter I. Duncan, Catherine F. Enters-Weijnen, et al. · Nutrients · 15

PDF

The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine

1996 · E. SNOECK, P. JACQMIN, et al. · British Journal of Clinical Pharmacology · 13

PDF

Efficacy And Safety Of Bradykinin B2 Receptor Inhibition With Oral PHVS416 In Treating Hereditary Angioedema Attacks: Results Of RAPIDe-1 Phase 2 Trial

2023 · Marcus Maurer, John Anderson, et al. · Journal of Allergy and Clinical Immunology · 12

PDF

Intermittent Recombinant Growth Hormone Treatment in Short Children Born Small for Gestational Age: Four-Year Results of a Randomized Trial of Two Different Treatment Regimens

2006 · D. Simon, J. Leger, et al. · Hormone Research in Paediatrics · 12

The Cyclophilin Inhibitor Debio-025 is a Potent Inhibitor of Hepatitis C Virus Replication in vitro With a Unique Resistance Profile

2007 · L COELMONT, J PAESHUYSE, et al. · Antiviral Research · 10

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial

2026 · Marcus Maurer, Marcin Stobiecki, et al. · The Lancet Haematology · 9

Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial

2026 · Emel Aygören-Pürsün, Marcin Stobiecki, et al. · The Lancet Haematology · 7

Efficacy And Safety Of Bradykinin B2 Receptor Antagonism With Oral Deucrictibant In Prophylaxis Of Hereditary Angioedema Attacks: Results Of CHAPTER-1 Phase 2 Trial

2024 · Marc Riedl, John Anderson, et al. · Journal of Allergy and Clinical Immunology · 7

The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans

2014 · Avantika Barve, Steven J. Kovacs, et al. · Clinical Pharmacology in Drug Development · 7

946 Pk-pd Modeling of Viral Kinetics During Treatment With Debio-025 Plus Pegylated Interferon Alpha-2a in Treatment-naive Hcv Patients

2009 · E. Herrmann, A. Käfer, et al. · Journal of Hepatology · 7

PDF

[88] Viral Kinetics During 14-day Treatment With Debio-025 Demonstrate Efficient Blocking of Viral Replication in Different Hcv Genotypes Without Signs of Emerging Viral Resistance

2007 · E. Herrmann, R. Flisiak, et al. · Journal of Hepatology · 6

PDF

755 SUSTAINED VIROLOGICAL RESPONSE AFTER 4-WEEK TREATMENT WITH DEBIO 025 MONOTHERAPY OR COADMINISTERED WITH PEG-IFNα2A IN HCV GENOTYPE 1 AND 3 PATIENTS

2010 · A. Horban, H. Berak, et al. · Journal of Hepatology · 5

A phase I trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered low-anticoagulant heparin (M6229) in critically ill sepsis patients

2025 · Niels van Mourik, Rombout B. E. van Amstel, et al. · Intensive Care Medicine Experimental · 4

PDF

PHA-022121: A Novel and Potent Bradykinin 2 Receptor Antagonist for Oral Treatment of Hereditary Angioedema

2021 · Raf Crabbé · Journal of Allergy and Clinical Immunology · 4

Works count: 51

Citation count: 933

H-index: 13

I10-index: 16